Repligen (NASDAQ:RGEN) Trading Down 6.3% – Should You Sell?

Repligen Corporation (NASDAQ:RGEN)’s share price dropped 6.3% during mid-day trading on Tuesday . The company traded as low as $169.41 and last traded at $169.6550. 460,096 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,014,037 shares. The stock had previously closed at $180.98.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent research reports. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. HSBC decreased their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Jefferies Financial Group restated a “hold” rating and set a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. Barclays raised their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada assumed coverage on Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $166.43.

Repligen Stock Performance

The business has a fifty day moving average of $153.08 and a 200-day moving average of $133.28. The company has a market cap of $9.49 billion, a PE ratio of 230.34, a P/E/G ratio of 3.22 and a beta of 1.03. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. ABS Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter valued at about $191,016,000. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the third quarter worth about $29,000. Los Angeles Capital Management LLC bought a new stake in Repligen during the 4th quarter valued at approximately $36,000. Farther Finance Advisors LLC boosted its position in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 104 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.